Criteria for Evaluation of Novel Markers of Cardiovascular RiskMark A. Hlatky, Peter W.F. Wilson, Sharon‐Lise T. Normand et al.|Circulation|2009Cited by 1.1k
Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart AssociationMatthew J. Feinstein, Wendy S. Post, Priscilla Y. Hsue et al.|Circulation|2019Cited by 639
Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 InfectionMichael J. Peluso, Timothy J. Henrich, Scott Lu et al.|The Journal of Infectious Diseases|2021Cited by 332
Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trialJean‐Claude Tardif, Guy Boivin, Nadia Bouabdallaoui et al.|The Lancet Respiratory Medicine|2021Cited by 271
Inflammation of the periodontium associates with risk of future cardiovascular eventsThomas E. Van Dyke, Ahmed Tawakol, Karim El Kholy et al.|Journal of Periodontology|2021Cited by 71